Download Unicorn Signals App

Powered By EquityPandit
Latest News

The US health regulator completes inspection of Lupin’s Nagpur plant

lupn_equitypandit

The US health regulator has completed inspection of Lupin’s Nagpur facility, without making any observation.

The company in a BSE filing, “announced successful completion of an inspection carried out by the United States Food and Drug Administration (USFDA) at its Nagpur facility. The inspection was concluded without any observations”. Moreover, its Nagpur facility manufactures oral solid products.

Read EquityPandit’s Technical Analysis of Lupin

Get Daily Prediction & Stocks Tips On Your Mobile